000148877 001__ 148877 000148877 005__ 20250122151650.0 000148877 0247_ $$2doi$$a10.1007/s40266-016-0392-z 000148877 0248_ $$2sideral$$a96251 000148877 037__ $$aART-2016-96251 000148877 041__ $$aeng 000148877 100__ $$aAbadia, B. 000148877 245__ $$aClinical Applications of Dexamethasone for Aged Eyes 000148877 260__ $$c2016 000148877 5203_ $$aThe risk of severe eye problems has been found to increase significantly with age, particularly between the fifth and sixth decades of life. Cataracts, dry eye, neovascular age-related macular degeneration, diabetic retinopathy and retinal vein occlusion (RVO) are very common and very different age-related ocular diseases that reduce the patient’s quality of life. The rationale for using corticosteroids to treat anterior and posterior ocular segment diseases is driven by inflammation. Dexamethasone, one of the most powerful corticosteroids available, is widely used for topical or intravitreal administration. Topical dexamethasone has proven efficacy for the management of postoperative inflammation in the anterior segment after cataract surgery and symptom relief in dry-eye disease. A new sustained-release 700 µg dexamethasone intravitreal implant (DEX) was recently approved for the treatment of macular edema following RVO, diabetic macular edema, or non-infectious uveitis, and its use is increasing, especially when other therapeutic agents have failed. The most common side effects are increased intraocular pressure and cataract formation. The potency of DEX, alone or in combination with other agents, makes DEX a promising option for treating several retinal diseases. 000148877 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000148877 590__ $$a2.769$$b2016 000148877 591__ $$aPHARMACOLOGY & PHARMACY$$b106 / 256 = 0.414$$c2016$$dQ2$$eT2 000148877 591__ $$aGERIATRICS & GERONTOLOGY$$b22 / 49 = 0.449$$c2016$$dQ2$$eT2 000148877 592__ $$a1.262$$b2016 000148877 593__ $$aPharmacology (medical)$$c2016$$dQ1 000148877 593__ $$aGeriatrics and Gerontology$$c2016$$dQ1 000148877 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000148877 700__ $$0(orcid)0000-0002-6202-2382$$aCalvo, P.$$uUniversidad de Zaragoza 000148877 700__ $$0(orcid)0000-0002-2914-2593$$aFerreras, A.$$uUniversidad de Zaragoza 000148877 700__ $$0(orcid)0000-0002-4476-6003$$aBartol, F. 000148877 700__ $$aVerdes, G. 000148877 700__ $$0(orcid)0000-0003-2389-8282$$aPablo, L.$$uUniversidad de Zaragoza 000148877 7102_ $$11004$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Oftalmología 000148877 773__ $$g33, 9 (2016), 639-646$$pDrugs aging$$tDRUGS & AGING$$x1170-229X 000148877 8564_ $$s471051$$uhttps://zaguan.unizar.es/record/148877/files/texto_completo.pdf$$yVersión publicada 000148877 8564_ $$s2056355$$uhttps://zaguan.unizar.es/record/148877/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000148877 909CO $$ooai:zaguan.unizar.es:148877$$particulos$$pdriver 000148877 951__ $$a2025-01-22-14:47:02 000148877 980__ $$aARTICLE